PureIMS is a pharmaceutical company with in house development and manufacturing capabilities. Development of new active pharmaceutical ingredients (API’s) and next generation inhalation solutions like the Cyclops is being performed in very close co-operation with the State University Groningen (RUG) Department of Pharmaceutical Technology and Biopharmacy (PTB) of Professor Dr. H.W. Frijlink.
PureIMS and the RUG are also working together with third party pharmaceutical companies with regard to unique pharmacotherapeutical treatment solutions.
PureIMS is located in Roden, The Netherlands.
The core activity of PureIMS is preparing micronized drug compounds for inhalation purposes. PureIMS provides effective dry powder inhalers i.e. the Twincer® or one of its successors, with a suitable dosage of API, in order to provide her patients with adequate pharmacotherapy.
The Twincer® is a CE registered, non-sterile, single use, pre-metered, breath activated dry powder inhaler (DPI) specifically designed to deliver fine particles (1-5 µm) of a dry powder dose while inhaling.
PureIMS has been established in collaboration between the RUG (Department of PTB), Linesbridge Pharma Group (LPG) and Interventional Medical Device Solutions (IMDS). Because of this unique partnership, PureIMS possesses a skilled, enthusiastic and passionate team of researchers, pharmacists, pharmacy assistants, pharmaceutical professionals, QA/RA officials and product and process developers.
PureIMS has a strong focus to the medical professionals and their patients. PureIMS strives to comply to the needs of patients and caregivers as much as possible.
The products of PureIMS are based on the optimization of the deposition of the dry powder medications into the peripheral airways. The drugs in their purest form are administered at a lower dose resulting in the same therapeutic effect.
Good performance of a dry powder inhaler depends on the achieved balance between three aspects.
Particle morphology affects penetration, deposition and absorption. Device will de-agglomerate the powder to deliver fine particles (1-5 µm) of a dry powder dose while inhaling. The patient will be instructed to perform the most optimal inhalation technique.
Over 60 potential active pharmaceutical ingredients (API) have been identified to be administered via dry powder inhalation. Some of these applications/ indications are:
- Infectious diseases
- Cystic Fibrosis (e.g. Colistimethate, Tobramycin, Aztreonam, Meropenem, Ceftazidim)
- Tuberculosis (e.g. Kanamycin, Amikacin)
- Antifungals (e.g. Amphotericin B)
- Diagnostics (Provocation test; e.g. Methacholin, Mannitol)
- Vaccination (e.g. Influenza, Ebola)
- Immunosuppression (e.g. Ciclosporin A)
- Antidotes (e.g. Epinephrin)
- Pulmonary hypertension (e.g. Sildenafil, Iloprost)
- Parkinson’s disease (e.g. Levodopa)
- Erectile dysfunction (e.g. Tadalafil, Sildenafil)
- Pain (e.g. Fentanyl, Morphine)
- Migraine (e.g. Triptans)
Besides the above mentioned potential applications, also API that are newly developed or under investigation can be administered via the lungs with this technique. Time to market is relatively short when utilizing existing well known API to create a more efficient treatment to the increase quality of life of our patients.
For more information and to explore possibilities you are invited to contact PureIMS.